Vir Biotechnology (VIR) Stock: Reaches 52-Week High as Three Big Catalysts Hit at Once

TLDR VIR stock jumped ~60% in premarket Tuesday after a major Astellas Pharma partnership for prostate cancer drug VIR-5500 The deal includes $335M upfront, plus up to $1.37B in future milestone payments Phase 1 data showed an 82% PSA50 decline rate in the highest dose patient group Q4 loss of 31 cents beat the 41-cent [...]

The post Vir Biotechnology (VIR) Stock: Reaches 52-Week High as Three Big Catalysts Hit at Once appeared first on Blockonomi.